American Journal of Epidemiology Vol. 130, No. 6: 1142-1151
Copyright © 1989 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
NONCONTRACEPTIVE ESTROGEN USE AND EPITHELIAL OVARIAN CANCER
1Slone Epidemiology Unit, School of Public Health, Boston University School of Medicine Brook-line, MA
2Department of Pathology, Brigham and Women's Hospital Boston, MA
3Department of Medicine, University of Pennsylvania School of Medicine Philadelphia, PA
4Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Institute New York, NY
5Gynecology Services, Memorial Sloan-Kettering Cancer Institute New York, NY
The relation of noncontraceptive estrogen use to epithelial ovarian cancer was evaluated in a case-control study conducted in hospitals mainly in the northeastern United States. There were 377 cases diagnosed within the year before hospital admission and 2,030 hospital controls; data were collected by interview in the hospital. Compared with women who never took noncontraceptive estrogens, the overall relative risk estimate for women whose estrogen use lasted at least one year and was not combined with progestogens or testosterone was 1.2 (95% confidence interval (Cl) 0.8–1.9), after taking into account risk factors for ovarian cancer. There were 55 cases of the endometrioid, clear cell, or malignant mixed mesodermal cell type; the corresponding relative risk estimate was 0.9 (95% Cl 0.3–3.0). There were 26 cases of undirferentiated cell type, with a relative risk estimate of 3.6 (95% Cl 1.2–11). Relative risk estimates were similar in a subset of the cases (57%) for which pathology slides were reviewed. For estrogen use of long duration, use of high-dose preparations, or use in the distant past, the relative risk estimates were not significantly different from 1.0. The estimates were elevated for some categories of use, but not consistently—for example, for an interval of 5–9 years since estrogen use began (relative risk (RR) = 2.7), but not after shorter or longer intervals, and for use of conjugated estrogens with a dose of 0.3 mg (RR = 3.2) or 1.25 mg (RR = 2.4), but not for doses of 0.625 mg or 2.5 mg. The relative risk estimate was also elevated for use by nulliparous women (RR = 2.4). The results suggest that, overall, noncontraceptive estrogen use is not associated with the risk of epithelial ovarian cancer. Furthermore, our data do not support the hypothesis that estrogens increase the risk of endometrioid ovarian cancer. The elevated estimates could be due to multiple stratification of the data, but they should be explored in further studies, given the lethality of ovarian cancer and the common use of estrogens by postmenopausal women.
estrogens; ovarian neoplasms
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. M. Greiser, E. M. Greiser, and M. Doren Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis Hum. Reprod. Update, September 1, 2007; 13(5): 453 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Lacey Jr., L. A. Brinton, M. F. Leitzmann, T. Mouw, A. Hollenbeck, A. Schatzkin, and P. Hartge Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst, October 4, 2006; 98(19): 1397 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Glud, S. K. Kjaer, B. L. Thomsen, C. Hogdall, L. Christensen, E. Hogdall, J. E. Bock, and J. Blaakaer Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer Arch Intern Med, November 8, 2004; 164(20): 2253 - 2259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, P. F. Coogan, J. R. Palmer, B. L. Strom, and L. Rosenberg Cigarette Smoking and Increased Risk of Mucinous Epithelial Ovarian Cancer Am. J. Epidemiol., January 15, 2004; 159(2): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Riman, P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson, and I. R. Persson Risk Factors for Invasive Epithelial Ovarian Cancer: Results from a Swedish Case-Control Study Am. J. Epidemiol., August 15, 2002; 156(4): 363 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Lacey Jr, P. J. Mink, J. H. Lubin, M. E. Sherman, R. Troisi, P. Hartge, A. Schatzkin, and C. Schairer Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer JAMA, July 17, 2002; 288(3): 334 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Riman, P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson, E. Weiderpass, and I. R. Persson Hormone Replacement Therapy and the Risk of Invasive Epithelial Ovarian Cancer in Swedish Women J Natl Cancer Inst, April 3, 2002; 94(7): 497 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rodriguez, A. V. Patel, E. E. Calle, E. J. Jacob, and M. J. Thun Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women JAMA, March 21, 2001; 285(11): 1460 - 1465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Ness and C. Cottreau Possible Role of Ovarian Epithelial Inflammation in Ovarian Cancer J Natl Cancer Inst, September 1, 1999; 91(17): 1459 - 1467. [Abstract] [Full Text] [PDF]
|
|